The work, led by Dr. Rui Su’s group at City of Hope, demonstrates that targeting the METTL1-mediated m⁷G pathway selectively disrupts leukemic stem cell function while largely sparing normal hematopoietic stem cells, highlighting a promising new therapeutic strategy for AML.
Key Discovery 1. m⁷G Modification Sustains Leukemia Stem Cell Translation
m⁷G on tRNAs has long been regarded as a structural modification that stabilizes these molecules. This study reveals an unexpected function: m⁷G acts as a switch for selective protein translation.
The authors showed that:
• Leukemia stem cells (LSCs) depend strongly on METTL1, the methyltransferase that deposits m⁷G on tRNAs.
• tRNA-Phe(GAA) is among the most abundant and METTL1-dependent tRNAs in LSCs.
• METTL1 loss sharply reduces m⁷G-modified tRNA-Phe(GAA), blocking translation of phenylalanine-codon-enriched transcripts.
• Ribosome stalling then activates the No-Go Decay (NGD) pathway, degrading incompletely translated mRNAs.
Together these results show that tRNA m⁷G modification directly governs translation efficiency and transcript stability in leukemia stem cells.
Key Discovery 2. Disrupting m⁷G Prevents Leukemia Stem Cell Homing
Perhaps the most striking finding is that tRNA m⁷G modification controls whether leukemia stem cells can home to the bone marrow.
The study identified HCK, a Src-family kinase in CXCR4-mediated signaling, as a critical downstream target. After METTL1 inhibition:
• HCK translation is markedly reduced.
• CXCR4 signaling becomes impaired.
• LSCs lose their ability to migrate toward CXCL12-rich bone marrow niches.
• Without microenvironmental protection, LSC self-renewal declines and leukemic progression is suppressed.
These results establish m⁷G-dependent translation as an essential regulator of leukemia stem cell fitness and niche adaptation.
Key Discovery 3. First-in-Class METTL1 Inhibitor Targets the m⁷G Axis
Building on these mechanistic insights, the investigators identified M1i (NSC137443) through high-throughput screening.
M1i directly inhibits METTL1, leading to:
• Reduced intracellular m⁷G levels.
• Selective depletion of leukemia stem cells.
• Suppression of AML progression in multiple mouse and patient-derived xenograft (PDX) models.
• Minimal effects on normal hematopoietic stem cells.
These findings position the METTL1-m⁷G pathway as an attractive therapeutic target for AML.
Research Spotlight: Why Analyze tRNA m⁷G Modification?
This study illustrates how tRNA modifications can selectively regulate protein synthesis, ribosome dynamics, stem cell biology, and disease progression. Comprehensive m⁷G profiling is increasingly important for understanding cancer stem cell biology, translational regulation, RNA modification-mediated gene expression, and precision oncology and drug discovery.
Accelerate Your m⁷G Research with Arraystar TRAC-seq
Arraystar TRAC-seq (tRNA Reduction and Alkylation Coupled Sequencing) enables transcriptome-wide, single-nucleotide profiling of tRNA m⁷G modifications, providing a powerful solution for investigating METTL1-dependent translational regulation.
Key Advantages
• Transcriptome-wide profiling of tRNA m⁷G modifications.
• Single-nucleotide resolution.
• Quantitative comparison across biological conditions.
• Bioinformatics analysis that is easy to interpret and reuse.